Punjab and central regulators have cancelled the manufacturing licenses of Jackson Laboratories following reports of spurious oxytocin injections linked to five deaths in Rajasthan. Investigations uncovered falsified quality records and repeated compliance failures at the firm's facilities.
What Happened
The manufacturing licenses for Jackson Laboratories have been cancelled by the Punjab Food and Drugs Administration and the Central Drugs Standard Control Organisation (CDSCO). This regulatory action follows a distressing incident in Kota, Rajasthan, where five women died after undergoing C-section deliveries between May 5 and May 17. Investigations into the medical supplies used during these procedures revealed that the 'Tocin' brand oxytocin injections administered to the patients contained only water and lacked the necessary active pharmaceutical ingredient.
Findings at the Manufacturing Facility
Inspections conducted at the company’s Amritsar unit by regulatory authorities reportedly uncovered severe lapses in manufacturing processes. Findings included the use of uncalibrated equipment and the deliberate falsification of quality control records. Officials noted significant discrepancies between the company’s internal testing registers and the actual methodologies used, suggesting a systemic effort to bypass safety standards. These violations have led to the drug being classified as 'Not of Standard Quality' by the Rajasthan drugs controller.
Historical Regulatory Issues
This is not the first time Jackson Laboratories has faced scrutiny. Records indicate a pattern of non-compliance with established Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The company had reportedly received 'stop production' orders as early as 2023 following reports of contaminated sterile injections affecting newborns. Despite those previous directives, evidence suggests the firm continued manufacturing, which has prompted broader questions regarding the effectiveness of drug quality enforcement in the region.
Business and Legal Context
The oxytocin market in India is estimated to be worth approximately ₹42 crore. While this represents a niche segment within the pharmaceutical industry, the current situation highlights the challenges posed by potential parallel supply chains that operate outside rigorous quality oversight. Jackson Laboratories has reportedly challenged the cancellation of its manufacturing licenses in court, making the legal status of the company’s operations a central focus for stakeholders.
What Investors Should Track
The primary monitorable for investors and stakeholders is the ongoing court proceeding regarding the license cancellation. Additionally, the outcome of independent batch testing by Rajasthan authorities will determine the extent of the product recall and potential liability under the Drugs and Cosmetics Act, which includes severe penalties for the distribution of spurious drugs. Future regulatory updates from the CDSCO regarding enforcement against similar manufacturing entities will also be important to watch for changes in the industry's quality compliance environment.